In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price target of $5.00.
Jason McCarthy has given his Buy rating due to a combination of factors related to Gain Therapeutics’ promising developments with their lead asset, GT-02287. This compound is currently in a Phase 1b study targeting Parkinson’s disease, and it has shown potential in preclinical models by restoring glucocerebrosidase (GCase) function, reducing toxic lipid substrates, and improving dopamine levels, which are crucial for Parkinson’s treatment.
Additionally, the upcoming interim data from the Phase 1b trial, expected by mid-2025, is anticipated to be a significant catalyst for the stock. The previous Phase 1 study in healthy subjects demonstrated not only target engagement but also an unexpected increase in GCase activity, which was a positive surprise. This promising data, along with the potential for further positive outcomes in Parkinson’s patients, underpins McCarthy’s optimistic outlook for Gain Therapeutics’ stock.
According to TipRanks, McCarthy is an analyst with an average return of -24.0% and a 23.64% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Medicus Pharma Ltd.